von Fournier D
Abteilung Gyn. Radiologie, Radiologische Universitätsklinik Heidelberg.
Radiologe. 1996 Apr;36(4):300-5. doi: 10.1007/s001170050076.
The Swedish Mammography-Screening trials have shown a long-term reduction in the mortality rate in women aged between 50-69 of up to 30%. The lower reduction in mortality observed in women aged 40-49 was not statistically significant. Long-term observation over 20 years) has shown that a radiation dose of 2.4 mGy for a 2-view-mammography per breast does not lead to an increase in occurrence of breast cancers. The advantage of screening with regard to a reduction in death rate, frequent use of breast cancerving therapy and the reduction by half in the average size of the tumor compared to control groups results in: A recommendation for quality controlled screening in Germany from the age of 50 to 70. The possible advantage for younger women must be examined in further trials. Screening in the form of a de-centralized check-up system is to be carried out by practising doctors in co-operation with hospitals which will be responsible for double findings, assessment of difficult cases and continuous cost evaluation. Quality assurance centres, reference and training centres are required. The mammography in curative check-ups will also benefit from a screening programme.
瑞典乳腺钼靶筛查试验表明,50至69岁女性的死亡率长期降低了30%。40至49岁女性死亡率降低幅度较小,且无统计学意义。20年的长期观察表明,每侧乳房进行双视角乳腺钼靶检查时,2.4毫戈瑞的辐射剂量不会导致乳腺癌发病率增加。与对照组相比,筛查在降低死亡率、频繁使用乳腺癌治疗方法以及将肿瘤平均大小减半方面的优势导致:德国建议对50至70岁女性进行质量控制的筛查。年轻女性可能获得的益处必须在进一步试验中进行研究。分散式检查系统形式的筛查将由执业医生与医院合作开展,医院将负责对重复检查结果、疑难病例评估以及持续成本评估。需要质量保证中心、参考和培训中心。治疗性检查中的乳腺钼靶检查也将从筛查计划中受益。